OLMA Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative therapies for women's cancers. The company’s primary focus is on creating novel treatments for breast cancer and other estrogen receptor (ER)-driven malignancies. Leveraging a deep understanding of hormone-driven cancers, Olema aims to address significant unmet needs in the oncology field through its specialized drug development pipeline.
The company’s lead product candidate, OP-1250, is a cutting-edge estrogen receptor (ER) antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials. OP-1250 is being evaluated for its efficacy in treating recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This novel agent represents a promising advance in targeted cancer therapy, aiming to improve patient outcomes by specifically degrading the ER and inhibiting its activity, thereby addressing a critical need in the treatment of hormone-sensitive breast cancer.
In addition to OP-1250, Olema Pharmaceuticals is actively exploring other potential therapies to broaden its impact in the field of women's oncology. The company is committed to advancing its research and development efforts to bring transformative treatments to market, with a focus on optimizing therapeutic efficacy and minimizing side effects for patients. Olema’s strategic approach involves leveraging proprietary technology platforms and collaborative partnerships to accelerate the development of its drug candidates.
Founded in 2006 and originally known as CombiThera, Inc., the company rebranded to Olema Pharmaceuticals, Inc. in March 2009 to better reflect its focus on oncology. Headquartered in San Francisco, California, Olema Pharmaceuticals continues to drive innovation in cancer therapy, with a commitment to advancing scientific research and improving the lives of women affected by cancer through targeted and effective treatment options.
|
